Methods for delivery of sirna to the spinal cord and therapies arising therefrom
AssigneesQuark Pharmaceuticals, Inc., Rutgers, The State University of New Jersey
InventorsElena Feinstein, Martin Grumet
Life of this patent
Estimating the term…
Abstract
The present application relates at least in part to methods for the administration of small interfering RNAs (siRNAs) to the spinal cord of a human or animal patient and also to a method of treatment for spinal cord injury and other diseases and disorders of the CNS. In particular, the application discloses methods to deliver an siRNA compound locally, directly and without the need for transduction vehicles and formulations in effective doses to the injured spinal cord to promote recovery of CNS function and or attenuation of allodynia.
Claims24
A method of treating or preventing neuropathic pain in a subject, comprising administering to the subject a double stranded RNA compound directed to a target gene selected from RhoA or TLR4, in an amount effective to treat or prevent neuropathic pain in the subject.
The method of claim or 1, wherein the neuropathic pain is associated with spinal cord injury or with peripheral nervous system injury.
A method of treating a subject suffering from a disease, a disorder or an injury of the CNS associated with expression of a target gene, comprising locally administering to the subject's spine a double stranded RNA compound directed to the target gene in an amount effective to treat the subject, wherein the target gene is selected from a gene set forth in Table A.
15-25. (canceled)
A method for restoring motor function in a subject, comprising locally administering to subject's spine a double stranded RNA compound directed to a target gene associated with a loss of motor function in the subject, in an amount effective to restore motor function in the subject.
28-30. (canceled)
A method of attenuating pain associated with expression of a target gene in a CNS in a subject suffering from injury of the CNS, comprising administering to the subject a double stranded RNA compound directed to the target gene, in an amount effective to attenuate pain in the subject, wherein the double stranded RNA compound is administered by lumbar injection.
(canceled)
A method of preserving white matter in the spinal cord of a subject suffering from injury of the CNS, comprising administering to the subject a double stranded RNA compound directed to a target gene in the CNS, in an amount effective to preserve white matter in the subject, wherein the double stranded RNA compound is administered by lumbar injection.
A method of preventing allodynia or promoting serotonergic fiber growth in a subject suffering from an injury of the CNS, comprising administering to the subject a double stranded RNA compound directed to a target gene in the CNS, in an amount effective to prevent allodynia or promote serotonergic fiber growth in the subject, wherein the double stranded RNA compound is administered by lumbar injection.
35-37. (canceled)
Dependencies are inferred from the claim text.